QDEL Stock Forecast: QuidelOrtho Corp. Price Predictions for 2026-2027
The 3 Wall Street analysts covering QuidelOrtho Corp. hold a median 12-month price target of $13 — +56.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 48 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores QuidelOrtho Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (86): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (16): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
QDEL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on QDEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +56.3% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 July 2026 | Citigroup | Maintains | Neutral | $13 → $18 |
| 1 July 2026 | JP Morgan | Maintains | Underweight | $11 → $12 |
| 7 May 2026 | Jefferies | Downgrade | Hold | — |
| 6 May 2026 | Citigroup | Maintains | Neutral | — |
| 10 Apr 2026 | UBS | Maintains | Neutral | — |
| 12 Feb 2026 | Citigroup | Maintains | Neutral | — |
| 21 Jan 2026 | UBS | Maintains | Neutral | — |
| 7 Nov 2025 | JP Morgan | Maintains | Underweight | — |
| 6 Nov 2025 | UBS | Maintains | Neutral | — |
| 7 Oct 2025 | Citigroup | Downgrade | Neutral | — |
| 7 Aug 2025 | UBS | Maintains | Neutral | — |
| 6 Aug 2025 | Citigroup | Maintains | Buy | — |
| 8 May 2025 | Jefferies | Upgrade | Buy | — |
| 8 May 2025 | UBS | Maintains | Neutral | — |
| 21 Apr 2025 | JP Morgan | Maintains | Underweight | — |
| 13 Feb 2025 | RBC Capital | Maintains | Outperform | — |
| 13 Feb 2025 | UBS | Maintains | Neutral | — |
| 11 Dec 2024 | Citigroup | Upgrade | Buy | — |
| 10 Dec 2024 | Jefferies | Initiates | Hold | — |
| 19 Sept 2024 | UBS | Upgrade | Neutral | $42 → $50 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for QDEL.
This page is one stock. Monday covers all of them.
QDEL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
QDEL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, QuidelOrtho Corp. returned −61.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
QDEL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.2×
- Price / book
- 0.3×
- EV / EBITDA
- 7.6×
Cheaper than 89% of US stocks
Cheaper than 91% of US stocks
Cheaper than 70% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 43.3%
- Operating margin
- 0.2%
- Net margin
- —
Higher than 54% of US stocks
Higher than 43% of US stocks
- Return on equity
- −19.3%
- Return on assets
- 0.0%
- Dividend yield
- —
Higher than 32% of US stocks
Higher than 43% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
QuidelOrtho Corp. has a market value of $570.9M and an enterprise value of $3.5B.
Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter grew 2.8% year on year.
Net income over the same four quarters: −$1.0B, a −39.2% net margin.
Diluted earnings per share, trailing twelve months: −$15.41.
Free cash flow in the twelve months to 30 June 2026: −$211.2M.
forward P/E: 6.3× — the forward figure prices analyst consensus estimates, not reported earnings.
QuidelOrtho Corp. employs 6,500 people — $411K of revenue per employee.
Data provided by Twelve Data
QDEL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at QDEL’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own QuidelOrtho Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about QDEL
What is the QDEL stock price forecast for 2026-2027?
The 3 Wall Street analysts covering QuidelOrtho Corp. have a median 12-month price target of $13, with estimates ranging from $12 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is QDEL stock a buy right now?
Of the 3 analysts covering QuidelOrtho Corp., 1 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks QuidelOrtho Corp. 48 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank QDEL?
As at 21 Nov 2026, QuidelOrtho Corp. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (86 of 100).
Will QDEL stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +56.3% from the last close, and Ticker Nerd's factor model ranks QuidelOrtho Corp. 48 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the QDEL stock forecast for 2030?
No analyst covering QuidelOrtho Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QDEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $20 over the next 12 months.
How has QDEL stock performed over the past year?
QuidelOrtho Corp. returned -61.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does QuidelOrtho Corp. do?
QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-care testing, labs, and transfusion medicine.
About QuidelOrtho Corp.
QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-care testing, labs, and transfusion medicine. Its offerings are designed to support disease detection, monitoring, and clinical decision-making in settings ranging from hospitals and reference laboratories to blood banks and other care environments. QuidelOrtho serves a global market and plays an important role in providing tools that help clinicians identify infections, manage chronic conditions, and support transfusion safety. Headquartered in San Diego, California, QuidelOrtho Corporation combines broad diagnostic expertise with a diversified portfolio that addresses both routine and specialized testing needs in modern healthcare.
CEO Mr. Brian J. Blaser · 6,500 employees · United States · https://www.quidelortho.com